down arrow

Olema Pharmaceuticals, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US68062P1066
USD
27.64
0.49 (1.8%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

26.9328.45

52 Week

2.8629.50
Valuation
Technical
Day's Volume

CASH

2.86 M

Shareholding (Mar 2025)

FII

12.96%

Held by 82 FIIs

DII

48.3%

Held by 27 DIIs

Promoter

20.31%

How big is Olema Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Olema Pharmaceuticals, Inc. has a market capitalization of 274.37 million and reported net sales of 0.00 million with a net profit of -128.89 million over the latest four quarters. Shareholder's funds are at 408.96 million and total assets at 556.07 million.

As of Jun 18, Olema Pharmaceuticals, Inc. has a market capitalization of 274.37 million, classifying it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 0.00 million, while the sum of Net Profit for the same period is -128.89 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 408.96 million and Total Assets at 556.07 million.

Read More

What does Olema Pharmaceuticals, Inc. do?

22-Jun-2025

Olema Pharmaceuticals, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $30 million and a market cap of $274.37 million. Key metrics include a negative P/E ratio, a 0.00% dividend yield, and a debt-to-equity ratio of -1.02.

Overview: <BR>Olema Pharmaceuticals, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -30 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 274.37 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.02 <BR>Return on Equity: -33.61% <BR>Price to Book: 0.72<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Olema Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, Olema Pharmaceuticals shows a bullish technical trend with strong weekly performance, despite some short-term bearish indicators, having outperformed the S&P 500 recently while underperforming over the past year.

As of 11 September 2025, the technical trend for Olema Pharmaceuticals, Inc. has changed from sideways to bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating positive momentum. However, the weekly RSI is bearish, suggesting some short-term weakness. The daily moving averages are bullish, reinforcing the overall positive trend. The KST shows a bullish weekly signal but is bearish monthly, which presents a mixed picture. Dow Theory indicates a mildly bullish stance on both weekly and monthly time frames. The Bollinger Bands are bullish weekly but sideways monthly, adding to the mixed signals.<BR><BR>In terms of performance, Olema Pharmaceuticals has outperformed the S&P 500 significantly over the past week (6.37% vs. 1.05%) and month (47.74% vs. 2.33%), while it has underperformed over the past year (-33.57% vs. 17.14%). Overall, the current technical stance is bullish, albeit with some short-term bearish indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 520 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.02

stock-summary
Return on Equity

-41.22%

stock-summary
Price to Book

1.51

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-44 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
339.43%
0%
339.43%
6 Months
582.47%
0%
582.47%
1 Year
176.4%
0%
176.4%
2 Years
89.57%
0%
89.57%
3 Years
912.45%
0%
912.45%
4 Years
163.99%
0%
163.99%
5 Years
-45.62%
0%
-45.62%

Olema Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Olema Pharmaceuticals, Inc. technically bullish or bearish?

As of 11 September 2025, the technical trend for Olema Pharmaceuticals, Inc. has changed from sideways to bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating positive momentum. However, the weekly RSI is bearish, suggesting some short-term weakness. The daily moving averages are bullish, reinforcing the overall positive trend. The KST shows a bullish weekly signal but is bearish monthly, which presents a mixed picture. Dow Theory indicates a mildly bullish stance on both weekly and monthly time frames. The Bollinger Bands are bullish weekly but sideways monthly, adding to the mixed signals. In terms of performance, Olema Pharmaceuticals has outperformed the S&P 500 significantly over the past week (6.37% vs. 1.05%) and month (47.74% vs. 2.33%), while it has underperformed over the past year (-33.57% vs. 17.14%). Overall, the current technical stance is bullish, albeit ...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-195.73%
EBIT to Interest (avg)
-96.21
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.02
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.80
EV to EBIT
0.61
EV to EBITDA
0.61
EV to Capital Employed
10.51
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
1735.02%
ROE (Latest)
-33.61%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 42 Schemes (18.42%)

Foreign Institutions

Held by 82 Foreign Institutions (12.96%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -44.08% vs -51.24% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-47.90",
          "val2": "-33.40",
          "chgp": "-43.41%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-43.80",
          "val2": "-30.40",
          "chgp": "-44.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -33.92% vs 7.73% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-141.90",
          "val2": "-104.60",
          "chgp": "-35.66%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-129.50",
          "val2": "-96.70",
          "chgp": "-33.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-47.90
-33.40
-43.41%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-43.80
-30.40
-44.08%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -44.08% vs -51.24% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-141.90
-104.60
-35.66%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-129.50
-96.70
-33.92%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -33.92% vs 7.73% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Olema Pharmaceuticals, Inc. stock-summary
stock-summary
Olema Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."